Annovis Bio Sets March 2027 Readout for Phase 3 Alzheimer’s Trial, Bolstered by $21 Million Financing

Annovis Bio's Q3 2026 update highlights full enrollment of its Phase 3 Alzheimer's trial and a planned March 2027 data readout, with new financing expected to fund operations through the milestone.

Chicago Metrowire Staff
••Healthcare
Annovis Bio Sets March 2027 Readout for Phase 3 Alzheimer’s Trial, Bolstered by $21 Million Financing

Annovis Bio Inc. (NYSE: ANVS) has provided third-quarter 2026 corporate updates that sharpen the timeline for its most advanced Alzheimer’s disease program and clarify how the company intends to fund the pivotal readout. The Phase 3 DUET-AD trial is now fully enrolled with 862 patients with early Alzheimer’s disease, and the company expects topline results from the six-month treatment period in March 2027. That date matters because the trial features two prespecified efficacy readouts—at six months and 18 months—designed to evaluate symptomatic and disease-modifying effects, respectively. A successful six-month result would provide the first late-stage evidence of buntanetap’s clinical profile and could position the company to proceed with a planned New Drug Application.

The company also said it plans to begin transitioning eligible patients into its Alzheimer’s open-label extension study by the end of November 2026. That step is important for retaining patients who may benefit from longer-term treatment and for generating safety data that regulators typically expect alongside an NDA. Annovis reported enrollment of 326 patients in its Parkinson’s disease open-label extension study, which is designed to evaluate the long-term safety and efficacy of buntanetap over 36 months. The Parkinson’s program broadens the potential label for the drug and gives the company a second source of late-stage data.

On the regulatory side, Annovis said in September it partnered with Weave Bio to support regulatory documentation and preparation of its planned NDA. The company subsequently closed an approximately $21 million underwritten public offering on Nov. 6, 2026, including a $5 million investment from its board chairman. Management said the financing is expected to support operations through the anticipated March 2027 topline data readout. That funding runway is significant because it reduces the near-term need for additional capital before the trial’s most consequential milestone.

The implications extend beyond Annovis. Buntanetap is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. If the approach succeeds, it would represent a differentiated strategy for neurodegenerative disease that targets several disease-related proteins simultaneously rather than focusing on a single pathway. The company, headquartered in Malvern, Pennsylvania, is a Phase 3 clinical-stage biotechnology company developing treatments for Alzheimer’s disease and Parkinson’s disease.

Investors can follow the company through its www.annovisbio.com and its corporate accounts on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS. The full press release can be viewed at https://ibn.fm/6c61g. The update was distributed through BioMedWire, part of the Dynamic Brand Portfolio at IBN, which provides InvestorWire distribution and editorial syndication to 5,000+ outlets. Terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.

Blockchain Registration

QR Code for Blockchain Registration